Immuno-Oncology | Specialty

MOA and Rationale for RET Inhibitor Development

March 30th 2020

The Importance of Targeting RET in NSCLC

March 30th 2020

The Future of Treatment for Soft Tissue Diseases

March 25th 2020

GIST Treatment: Durability of Response and Challenges

March 25th 2020

Use of Targeted Therapy in GIST Mutations

March 25th 2020

Targeted Therapy Advancements in Sarcoma Subtypes

March 25th 2020

Soft Tissue Sarcoma: Unmet Needs

March 25th 2020

The Prognostic Value of Molecular Testing

March 25th 2020

Switching Therapy: Secondary Mutations and Resistance

March 25th 2020

Current Treatment Landscape of Soft Tissue Sarcoma

March 25th 2020

Diagnostic Testing Procedure for Soft Tissue Sarcoma

March 25th 2020

Dr. Brody on In Situ Vaccinations for Hematologic Cancers

February 28th 2020

Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.

Future Directions for Later-Line Therapy in R/R mCRC

February 25th 2020

Role of Immunotherapy in Microsatellite-Stable R/R mCRC

February 25th 2020

Relapsed/Refractory mCRC: Immunotherapy in MSI-High Tumors

February 25th 2020

Management of R/R mCRC: Sequencing for Later-Line Therapies

February 25th 2020

R/R Metastatic CRC: CORRECT, IMblaze370, and ReDOS Trials

February 25th 2020

Third-line and Later-line Therapies in R/R mCRC

February 25th 2020

Role of Rebiopsy and ctDNA Testing at Progression of mCRC

February 25th 2020

Molecular Status and Subsequent Therapies in mCRC

February 25th 2020